Estrella Non Current Liabilities Other from 2010 to 2024
| ESLA Stock | 1.14 0.10 9.62% |
Non Current Liabilities Other | First Reported 2010-12-31 | Previous Quarter 11.5 K | Current Value 11 K | Quarterly Volatility 1.3 K |
Check Estrella Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Estrella Immunopharma's main balance sheet or income statement drivers, such as Tax Provision of 1.7 K, Depreciation And Amortization of 246.2 K or Selling General Administrative of 3.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 8.39. Estrella financial statements analysis is a perfect complement when working with Estrella Immunopharma Valuation or Volatility modules.
Estrella | Non Current Liabilities Other |
Latest Estrella Immunopharma's Non Current Liabilities Other Growth Pattern
Below is the plot of the Non Current Liabilities Other of Estrella Immunopharma over the last few years. It is Estrella Immunopharma's Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Estrella Immunopharma's overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Other | 10 Years Trend |
|
Non Current Liabilities Other |
| Timeline |
Estrella Non Current Liabilities Other Regression Statistics
| Arithmetic Mean | 14,206 | |
| Geometric Mean | 14,142 | |
| Coefficient Of Variation | 9.32 | |
| Mean Deviation | 989.60 | |
| Median | 14,825 | |
| Standard Deviation | 1,324 | |
| Sample Variance | 1.8M | |
| Range | 3.8K | |
| R-Value | (0.69) | |
| Mean Square Error | 982,226 | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (204.89) | |
| Total Sum of Squares | 24.5M |
Estrella Non Current Liabilities Other History
About Estrella Immunopharma Financial Statements
Estrella Immunopharma stakeholders use historical fundamental indicators, such as Estrella Immunopharma's Non Current Liabilities Other, to determine how well the company is positioned to perform in the future. Although Estrella Immunopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Estrella Immunopharma's assets and liabilities are reflected in the revenues and expenses on Estrella Immunopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Estrella Immunopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Other | 11.5 K | 11 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Estrella Immunopharma is a strong investment it is important to analyze Estrella Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Estrella Immunopharma's future performance. For an informed investment choice regarding Estrella Stock, refer to the following important reports:Check out the analysis of Estrella Immunopharma Correlation against competitors. For information on how to trade Estrella Stock refer to our How to Trade Estrella Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. If investors know Estrella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Estrella Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.24) | Return On Assets (1.22) | Return On Equity (2.78) |
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Estrella Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Estrella Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Estrella Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.